A US Food and Drug Administration panel’s positive review of Aimmune Therapeutics Inc.’s peanut allergy oral immunotherapy Palforzia would seem to bode well for DBV Technologies SA’s epicutaneous immunotherapy Viaskin Peanut, assuming the latter’s resubmitted application is up to snuff on manufacturing and the firm is prepared with a Risk Evaluation and Mitigation Strategy.
Although some analysts see the DBV patch product as having a more attractive safety profile than Aimmune’s Palforzia, the recent...






